Search

Your search keyword '"Ferrán M"' showing total 12 results
Start Over Author "Ferrán M" Publication Type Magazines
12 results on '"Ferrán M"'

1. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM

Author

Nieto Benito, L.M., Carretero, G., Rivera-Díaz, R., Carrascosa, J.M., Daudén, E., de la Cueva, P., Sahuquillo-Torralba, A., Herrera-Acosta, E., Baniandrés-Rodríguez, O., Lopez-Estebaranz, J.L., Belinchón, I., Riera-Monroig, J., Ferrán, M., Gómez-García, F.J., Mateu, A., Rodríguez, L., Vilar-Alejo, J., García-Donoso, C., Ballescá, F., Velasco, Llamas-M., Botella-Estrada, R., Herrera-Ceballos, E., Ruiz-Genao, D.P., Descalzo, M.A., and García-Doval, I.

Published
2022
Full Text
View/download PDF

3. Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm

Author

Galiano Mejías, S., Carretero, G., Ferrandiz, C., Vanaclocha, F., Daudén, E., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón-Romero, I., Sánchez-Carazo, J.L., López-Estebaranz, J.L., Alsina, M., Ferrán, M., Torrado, R., Carrascosa, J.M., Rivera, R., Llamas-Velasco, M., Jiménez-Puya, R., Mendiola, Mª V., Ruiz-Genao, D., Descalzo, M.A., and de la Cueva Dobao, P.

Published
2017
Full Text
View/download PDF

4. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

Author

Galiano Mejías, S., Carretero, G., Ferrandiz, C., Vanaclocha, F., Daudén, E., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón-Romero, I., Sánchez-Carazo, J.L., López-Estebaranz, J.L., Alsina, M., Ferrán, M., Torrado, R., Carrascosa, J.M., Rivera, R., Llamas-Velasco, M., Jiménez-Puya, R., Mendiola, Mª V., Ruiz-Genao, D., Descalzo, M.A., and de la Cueva Dobao, P.

Published
2017
Full Text
View/download PDF

5. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

Author

Carrascosa, J.M., Rivera, N., Garcia-Doval, I., Carretero, G., Vanaclocha, F., Daudén, E., Gómez-García, F.J., De-la-Cueva-Dobao, P., Herrera-Ceballos, E., Belinchón, I., Alsina, M., Sánchez-Carazo, J.L., Ferrán, M., Lopez-Estebaranz, J.L., Pérez-Zafrilla, B., Llamas, M., Rivera, R., and Ferrándiz, C.

Abstract

With the advent of biologic drugs in the management of moderate to severe psoriasis, there may have been a shift in therapeutic approach from rotational strategies to a unidirectional progression from topical treatments to the highest rung of the therapeutic ladder. We studied the frequency of switching from classic to biologic therapy and vice versa in a cohort of patients with psoriasis over a period of up to 5 years.

Published
2015
Full Text
View/download PDF

6. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

Author

Carrascosa, J.M., Rivera, N., Garcia-Doval, I., Carretero, G., Vanaclocha, F., Daudén, E., Gómez-García, F.J., De-la-Cueva-Dobao, P., Herrera-Ceballos, E., Belinchón, I., Alsina, M., Sánchez-Carazo, J.L., Ferrán, M., Lopez-Estebaranz, J.L., Pérez-Zafrilla, B., Llamas, M., Rivera, R., and Ferrándiz, C.

Abstract

With the advent of biologic drugs in the management of moderate to severe psoriasis, there may have been a shift in therapeutic approach from rotational strategies to a unidirectional progression from topical treatments to the highest rung of the therapeutic ladder. We studied the frequency of switching from classic to biologic therapy and vice versa in a cohort of patients with psoriasis over a period of up to 5 years.

Published
2015
Full Text
View/download PDF

7. Enfermedades inflamatorias mediadas por inmunidad y otras comorbilidades en pacientes con psoriasis. Características basales de la cohorte de pacientes con psoriasis del estudio AQUILES

Author

Vanaclocha, F., Crespo-Erchiga, V., Jiménez-Puya, R., Puig, L., Sánchez-Carazo, J.L., Ferrán, M., Sancho, C., Juliá, B., Cea-Calvo, L., Marín-Jiménez, I., and García-Vicuña, R.

Abstract

Los pacientes con psoriasis presentan con frecuencia comorbilidades, incluyendo otras enfermedades inflamatorias mediadas por inmunidad (EIMI) y factores de riesgo cardiovascular (FRCV). El objetivo de este trabajo es describir la prevalencia basal de otras EIMI y comorbilidades en una cohorte de pacientes con psoriasis.

Published
2015
Full Text
View/download PDF

8. Immune-Mediated Inflammatory Diseases and Other Comorbidities in Patients With Psoriasis: Baseline Characteristics of Patients in the AQUILES Study

Author

Vanaclocha, F., Crespo-Erchiga, V., Jiménez-Puya, R., Puig, L., Sánchez-Carazo, J.L., Ferrán, M., Sancho, C., Juliá, B., Cea-Calvo, L., Marín-Jiménez, I., and García-Vicuña, R.

Abstract

Patients with psoriasis often have comorbidities, including other immune-mediated inflammatory diseases (IMIDs), and cardiovascular risk factors. In this article we describe the baseline prevalence of comorbidities—including other IMIDs—in a cohort of patients with psoriasis.

Published
2015
Full Text
View/download PDF

9. Clinical Characteristics and Disease Course in Patients Treated With Efalizumab Following Suspension of Marketing Authorization by the European Medicines Agency: A Multicenter Observational Study

Author

Morell, L., Carrascosa, J.M., Ferrándiz, C., García-Bustinduy, M., Fonseca, E., Carretero, G., Daudén, E., Marrón, S.E., López-Estebaranz, J.L., Ferrán, M., Sánchez-Regaña, M., Muñoz-Santos, C., Belinchón, I., and Puig, Luis

Abstract

The withdrawal of marketing authorization for efalizumab by the European Medicines Agency in February, 2009 provided a unique opportunity to assess the course of disease in patients who were not subject to the selection criteria and biases that were common in the pivotal trials. The aim of this study was to evaluate the course of psoriasis following forced suspension of efalizumab in a group of patients treated in normal clinical practice. As secondary objectives, we sought to assess the relationships between clinical characteristics, treatment response, and disease course during efalizumab treatment and 12 and 24 weeks after suspension.

Published
2011
Full Text
View/download PDF

10. BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report

Author

Rivera, R., García-Doval, I., Carretero, G., Daudén, E., Sánchez-Carazo, J., Ferrándiz, C., Herrera, E., Alsina, M., Ferrán, M., López-Estebaranz, J.L., Gómez, F., Herranz, J.M., Carrascosa, J.M., and Vanaclocha, F.

Abstract

The Working Group on Psoriasis of the Spanish Academy of Dermatology and Venereology has initiated BIOBADADERM, a registry of patients with psoriasis receiving treatment with biologic drugs, in order to assess the long-term risk of adverse events (AEs).

Published
2011
Full Text
View/download PDF

11. [Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

Author

Nieto Benito, L.M., Carretero, G., Rivera-Díaz, R., Carrascosa, J.M., Daudén, E., de la Cueva, P., Sahuquillo-Torralba, A., Herrera-Acosta, E., Baniandrés-Rodríguez, O., Lopez-Estebaranz, J.L., Belinchón, I., Riera-Monroig, J., Ferrán, M., Gómez-García, F.J., Mateu, A., Rodríguez, L., Vilar-Alejo, J., García-Donoso, C., Ballescá, F., Velasco, L.-M., Botella-Estrada, R., Herrera-Ceballos, E., Ruiz-Genao, D.P., Descalzo, M.A., and García-Doval, I.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results